Key Takeaways
- Avecho Biotechnology received $1.98 million under the Australian Government’s R&D Tax Incentive Scheme.
- The funding will primarily repay $1.62 million to Endpoint Capital and support ongoing operations.
- Avecho’s lead product, a CBD TPM soft-gel capsule for insomnia, is in Phase III clinical trials.
Funding Announcement and Future Plans
Avecho Biotechnology Limited (ASX: AVE) has confirmed the receipt of $1.98 million through the Australian Government’s Research and Development (R&D) Tax Incentive Scheme for the year ending December 31, 2025. This funding supports the development and commercialization of innovative health products leveraging the company’s proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®), which enhances the solubility and absorption of drugs and nutrients.
The R&D Tax Incentive Scheme is designed to help Australian businesses offset expenses related to critical research and development activities. This financial support highlights Avecho’s dedication to innovation and its ongoing R&D efforts.
Most of the funds will be allocated to repay Endpoint Capital $1.62 million for advances received on the company’s R&D tax credit last year. Remaining funds will be directed toward supporting ongoing operations and advancing Avecho’s commercialization strategy.
Avecho also aims to develop unique cannabinoid formulations for pharmaceutical registration, further expanding its product offerings. Its leading asset, a proprietary cannabidiol (CBD) TPM soft-gel capsule, is currently in a critical Phase III clinical development program targeting insomnia treatment. Continued advancement of this and other projects is crucial to Avecho’s mission of delivering innovative medicines to patients worldwide.
The content above is a summary. For more details, see the source article.